2. 2
Objectives
⢠Classify antiepileptic drugs
⢠Describe pharmacology of antiepileptic drugs
â Mechanism of action
â Relevant pharmacokinetics
â Indications
â Adverse drug reactions
â Important drug interactions
⢠Explain pharmacological management of
epilepsy
3.
4. MECHANISM OF ACTION OF ANTIEPILEPTIC DRUGS
Three main mechanisms â
⢠Enhancement of GABA action
⢠Inhibition of sodium channel function
⢠Inhibition of calcium channel function.
Other mechanisms include -
- Inhibition of glutamate release and
- Block of glutamate receptors.
5. 5
Classification of Anticonvulsants
Action on Ion
Channels
Enhance
GABA
Transmission
Inhibit EAA
Transmissi
on
Na+:
Phenytoin,
Carbamazepine,
Lamotrigine
Topiramate
Valproic acid
Ca++:
Ethosuximide
Valproic acid
Benzodiazepines
(diazepam,
clonazepam)
Barbiturates
(phenobarbital)
Valproic acid
Gabapentin
Vigabatrin
Topiramate
Felbamate
Felbamate
Topiramate
6. Mechanism of action of antiepileptic
drugs
ďśPhenytoin, Carbamazepine,
felbamate, lamotrigine, valproic acid
⢠Block voltage-dependent sodium
channels at high firing frequencies
7. Mechanism of action of antiepileptic drugs
ďś Barbiturates
⢠Prolong GABA-mediated chloride
channel openings
ďś Benzodiazepines
⢠Increase frequency of GABA-
mediated chloride channel
openings
7
8. Valproate
ďś May enhance GABA transmission in
specific circuits
ďś Blocks voltage-dependent sodium channels
ďś Blocks T-type calcium currents
Ethosuximide
⢠Blocks slow, threshold, âtransientâ (T-type) calcium
channels in thalamic neurons
8
Mechanism of action of antiepileptic drugs(AEDs)
9. Newer AEDs: mechanism of action
Vigabatrin: Irreversibly inhibits GABA transaminase
Tiagabine: Interferes with GABA re-uptake
Topiramate:
â Blocks voltage-dependent sodium channels at high
firing frequencies
â Increases frequency at which GABA opens Cl-
channels (different site from benzodiazepines)
â Antagonizes glutamate actions at receptor subtype
Gabapentin: May modulate amino acid transport into brain &
May interfere with GABA re-uptake
9
10. Phenobarbitone
⢠GABA-facilitatory
⢠GABA-mimetic
⢠Adverse effects
â sedative action.
â Long term administration - behavioral
abnormalities, impairment of learning and
memory, hyperactivity in children, mental
confusion in older people.
â Rashes, megaloblastic anaemia and osteo-
malacia on prolonged use.
11. Uses/indications
⢠Generalized tonic-clonic (GTC), simple partial
(SP) and complex partial (CP) seizures:
60 mg 1-3 times a day in adults; in children (3-6
mg/kg/ day).
⢠Status epilepticus: may be injected i.m. or i.v.
but response is slow to develop.
⢠not effective in absence seizures.
12. Phenytoin (Diphenylhydantoin)
⢠Most commonly used.
⢠Phenytoin prolongs the inactivated state of
voltage sensitive neuronal Na+ channel and
reduces the neuronal excitability.
13. Pharmacokinetics
⢠Absorption is formulation dependent
⢠highly bound to plasma proteins
⢠fosphenytoin is for IV, IM routes
⢠The kinetics changes from first order to zero
order over the therapeutic range(small
increments in dose produce
disproportionately high plasma
concentrations.)
⢠The t1/2 - 12-24 hours progressively âes upto
60 hr when plasma concentration rises above
10 ug/ml as metabolizing enzymes get
saturated.
14. Adverse effect
At therapeutic levels -
⢠Gum hypertrophy:
⢠Hirsutism:
⢠Hypersensitivity reactions:
⢠Megaloblastic anaemia:
⢠Osteomalacia:
⢠Hyper-glycaemia.
⢠foetal hydantoin syndrome (hypoplastic phalanges, cleft
palate, hare lip, microcephaly),due to its areneoxide
metabolite.
15. Adverse effect
At high plasma levels (dose related toxicity)
⢠CNS- Cerebellar and vestibular manifestations:
ataxia, vertigo, diplopia, nystagmus are the most
characteristic features.
Drowsiness, behavioral alterations, mental
confusion and hallucinations.
⢠GIT - Epigastric pain, nausea and vomiting:
minimised by taking the drug with meals.
⢠CVS â hypotension & arrhythmias.
16. Uses
⢠Generalized tonic-clonic, simple and comp
lex partial seizures.
⢠It is ineffective in absence seizures.
Dose: 100 mg BD, maximum 400 mg/day; Children 5-8
mg/kg/day,
⢠Status epilepticus: occasionally used by slow
i.v. injection.
⢠Trigeminal neuralgia - second choice drug to
carbamazepine.
17. Carbamazepine
⢠Adverse effects
â Dose related neurotoxicityâsedation, dizziness,
vertigo, diplopia and ataxia.
â Vomiting, diarrhea
â Acute intoxication - coma, convulsions and
cardiovascular collapse.
â Hypersensitivity reactions:rashes,photosensitivity
hepatitis, lupus like syndrome
â Water retention and hyponatremia in the elderly as it
enhances ADH action.
â Teratogenic
18. Uses
⢠It is the most effective drug for CPS
⢠First choice drug with phenytoin for GTC and
SPS .
⢠Trigeminal and related neuralgias - is the drug
of choice.
⢠Manic depressive illness and acute mania - as
an alternative to lithium
19. ETHOSUXIMIDE
⢠Inhibit T type Ca+2 current in thalamic
neurons.
⢠Adverse effects
â GI intolerance, tiredness, mood changes,
agitation, headache, drowsiness and inability
to concentrate
⢠Uses
â Only in ABSENCE SEIZURES but Use has now
declined as many consider valproic acid to be
superior to it.
20. VALPROIC ACID (Sodium Valproate)
Multiple mechanisms of action :
⢠Phenytoin like frequency dependent
prolongation of Na* channel inactivation.
⢠Attenuation of Ca2+ mediated 'T' current
(ethosuximide like)
⢠Augmentation of release of inhibitory
transmitter GABA by inhibiting its degradation
(by GABA-transaminase) & by increasing its
synthesis.
21. Uses
⢠Highly effective in absence seizure.
⢠Alternative /adjuvant drug for GTCS, SPS and
CPS.
⢠Myoclonic and atonic seizuresâcontrol is
often incomplete, but it is the drug of choice.
⢠Mania and bipolar illness: as alternative to
lithium.
22. Adverse effects
⢠anorexia, vomiting, loose motions, heart burn
⢠Drowsiness, ataxia, tremors
⢠Alopecia, curling of hair, increased bleeding
tendency
⢠Fulminant hepatitis (very rare0
⢠Pancreatitis
⢠High incidence of PCOD in young girls
⢠Teraotogenic
22
23. LAMOTRIGINE
Blocks sodium as well as high voltage
dependent calcium channels
Uses
⢠Broad spectrum antiepileptic.
⢠Refractory cases of partial seizures and GTCS
⢠Absence and myoclonic or akinetic epilepsy .
⢠Lennox-gastaut syndrome
Adverse effects
⢠sleepiness, dizziness, diplopia,ataxia and vomiting.
⢠better tolerated than carbamazepine or phenytoin.
⢠Rash may be a severe
24. GABAPENTIN
⢠Enhances GABA release in brain.
⢠does not act as agonist at GABAA receptor.
⢠Reduces seizure frequency in refractory partial
seizures with or without generalization.
⢠Effective in SPS and CPS
⢠Manic depressive illness and migraine
⢠first line drug for pain - diabetic neuropathy and
postherpetic neuralgia,
⢠Adverse effects - mild sedation, tiredness, dizziness
and unsteadiness.
25. VIGABATRIN
⢠Inhibitor of GABA-transaminase which degrades
GABA
⢠Effective in refractory epilepsy, specially partial
seizures with or without generalization.
⢠Adverse effects- behavioral changes, depression
and psychosis . drowsiness, amnesia, visual field
contraction, motor disturbances, agitation in
children.
26. TIAGABINE
⢠Recently developed anticonvulsant -
potentiates GABA mediated neuronal
inhibition by depressing GABA transporter
GAT-1 which removes synaptically released
GABA into neurons & glial cells.
⢠Uses â add on therapy of partial seizures with
or without secondary generalization.
⢠Adverse effects- mild sedation, nervousness,
asthenia, amnesia & abdominal pain.
metabolized in liver by hydroxylation and glucuronide conjugation.
Commonest , more in younger patients.
coarsening of facial features, acne.
Megaloblastic anaemia: phenytoin decreases folate absorption and increases its excretion.
Hypersensitivity reactions: Rashes, DLE,lymphadenopathv; neutropenia is rare butrequires discontinuation of therapy
Osteomalacia: increase metaboism of vit. D and interferes with calcium metabolism.
inhibit insulin release and cause hyper-glycaemia.
Used during pregnancyâcan produce foetal hydantoin syndrome (hypoplastic phalanges, cleft palate, hare lip, microcephaly),due to its areneoxide metabolite.